Ipca Laboratories Limited
IPCALAB
Rang in aandelen
#3414
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures... Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, diabetes, dermatology, diabetology, emollients/protectives, fever, gastroenterology, helminthics, hepatoprotectives, immunosuppressant, infectious diseases, malaria, neurology, neuropathic pain, and NSAIDs, as well as nutraceuticals, ophthalmology, oral anti diabetes drug, orthopedics, probiotics, psychiatry, respiratory, rheumatology, and urology. The company also exports its products worldwide. Ipca Laboratories Limited was incorporated in 1949 and is based in Mumbai, India.
Aandeelprijs
$20.02
Laatst gesynchroniseerd: 2026-10-19
Marktkapitalisatie
$5.08B
Verandering (1 dag)
-1.65%
Verandering (1 jaar)
38.46%
Land
IN
Handel Ipca Laboratories Limited (IPCALAB)
Categorie
Healthcare
P/B-ratio voor Ipca Laboratories Limited (IPCALAB)
P/B-ratio op October 2026 TTM: 6.01
Volgens de meest recente financiële rapporten en aandelenkoers van Ipca Laboratories Limited is de huidige P/B-ratio (TTM) 6.01. Eind 2024 had het bedrijf een P/B-ratio van 4.97.
P/B-ratiohistoriek voor Ipca Laboratories Limited van 2005 tot 2026
P/B-ratio aan het einde van elk jaar
| Jaar | P/B-ratio | Wijzigen |
|---|---|---|
| 2026 (TTM) | 6.01 | 18.32% |
| 2025 | 5.08 | 2.13% |
| 2024 | 4.97 | 41.30% |
| 2023 | 3.52 | -28.52% |
| 2022 | 4.92 | -3.99% |
| 2021 | 5.13 | 5.76% |
| 2020 | 4.85 | 23.20% |
| 2019 | 3.94 | 26.08% |
| 2018 | 3.12 | -2.65% |
| 2017 | 3.21 | -1.40% |
| 2016 | 3.25 | -10.50% |
| 2015 | 3.63 | -33.22% |
| 2014 | 5.44 | 27.37% |
| 2013 | 4.27 | 26.78% |
| 2012 | 3.37 | -6.01% |
| 2011 | 3.58 | -7.79% |
| 2010 | 3.89 | 195.76% |
| 2009 | 1.31 | -49.85% |
| 2008 | 2.62 | -17.46% |
| 2007 | 3.18 | 34.15% |
| 2006 | 2.37 | 2.83% |
| 2005 | 2.30 | 0.00% |
P/B-ratio voor vergelijkbare bedrijven of concurrenten
| Bedrijf | P/B-ratio | Verschil in P/B-ratio | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| 5.041 | -16.13% |
IN
|
